{"id":18519,"date":"2024-03-27T11:05:05","date_gmt":"2024-03-27T11:05:05","guid":{"rendered":"https:\/\/2023.re-check.ch\/?page_id=18519"},"modified":"2024-10-27T14:58:33","modified_gmt":"2024-10-27T14:58:33","slug":"birth-control-pills","status":"publish","type":"page","link":"https:\/\/www.re-check.ch\/en\/projects\/birth-control-pills\/","title":{"rendered":"Birth Control Pills"},"content":{"rendered":"\n
\n
\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n\n
\n

With a target population of millions of women, contraceptive drugs are among the pharmaceutical classes the industry is most interested in. Birth control pills are indeed a mass market product. However, in the early years of 2000’s emerging signals and studies showed that the oral contraceptives of \u201cnew generation\u201d come with a thrombosis and pulmonary embolism risk two to four times greater than the older pills.<\/p>\n\n\n\n

The saga of birth control pills of 3rd<\/sup> and 4th<\/sup> generation is a textbook case of health and regulatory system dysfunction: conflicts of interest, biased studies, a lot of money and many lies.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n

Investigative documentaries:<\/h2>\n\n\n\n

They have been promoted as \u201clighter\u201d and marketed as life-style products \u2013 a magic bullet against acne and premenstrual syndrome. However, 3rd<\/sup> and 4th<\/sup> generation of birth control pills bring more risks than the older generation’ ones. Three TV investigative stories by Serena Tinari featured the regulatory history of these contraceptives, their marketing, and the maze of conflicts of interest that surround their prescription.<\/p>\n\n\n\n

\n